Clinical Combination Strategies with Oncolytic Vaccines in Solid Tumours

Time: 3:30 pm
day: Day Two


• Harnessing the clinical activity of oncolytic adenoviral vector ONCOS-102 in solid tumours of different origin
• Identifying strong and consistent patterns of immuno-modulation with both PD1 blockade and chemotherapy
• Utilising the selection of future combination strategies based on tumour biopsy translational data